Jazz Pharmaceuticals — Third Quarter 2026 Earnings Summary

Jazz Pharmaceuticals reported third-quarter 2026 total revenues of $1.243 billion, representing a 10% year-over-year increase driven by strong performance from Xywav, Zepzelca, and the newly launched Ziihera. The company raised its full-year 2026 revenue guidance to a range of $4.775 billion to $4.85 billion following the acquisition of Actio Biosciences, which added the rare epilepsy therapy ABS-1230 to its portfolio. Despite a GAAP net loss of $483.4 million due to $754 million in acquired in-process research and development expenses, the company generated $1.3 billion in cash from operations during the first nine months of the year.